We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current FHTX market cap is 445.3M. The company's latest EPS is USD -1.7705 and P/E is -4.52.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 5.6M | 17.48M | 5.77M | 5.05M | 6.89M |
Operating Income | -32.05M | -17.08M | -30.78M | -28.19M | -26.63M |
Net Income | -29.49M | -14.35M | -24.11M | -25.02M | -22.98M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 430k | 1.32M | 19.23M | 34.16M |
Operating Income | -51.08M | -68.53M | -100.73M | -117.14M | -107.91M |
Net Income | -51.13M | -68.8M | -101.32M | -108.88M | -98.43M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 339.58M | 313.42M | 285.92M | 255M | 328.59M |
Total Liabilities | 388.93M | 370.81M | 363.11M | 352.49M | 342.91M |
Total Equity | -49.35M | -57.39M | -77.19M | -97.49M | -14.32M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 22.34M | 255.59M | 519.77M | 404.88M | 285.92M |
Total Liabilities | 23.81M | 109.41M | 422.9M | 404.77M | 363.11M |
Total Equity | -88.02M | 146.19M | 96.87M | 112k | -77.19M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -63.36M | -90.57M | -118.11M | -29.35M | -54.88M |
Investing | 68.64M | 107.07M | 144.45M | 27.1M | 9.12M |
Financing | 205k | 1.59M | 1.78M | 1.17M | 104.37M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -46.34M | -31.29M | -50.25M | 193.61M | -118.11M |
Investing | -964k | -108.91M | 36.17M | -244.32M | 144.45M |
Financing | 23.97M | 217.47M | 22.42M | 1.76M | 1.78M |
Market Cap | 445.3M |
Price to Earnings Ratio | -4.52 |
Price to Sales Ratio | 13.04 |
Price to Cash Ratio | 5.54 |
Price to Book Ratio | -5.77 |
Dividend Yield | - |
Shares Outstanding | 55.59M |
Average Volume (1 week) | 159.75k |
Average Volume (1 Month) | 132.78k |
52 Week Change | 88.92% |
52 Week High | 10.25 |
52 Week Low | 2.70 |
Spread (Intraday) | 5 (50%) |
Company Name | Foghorn Therapeutics Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.foghorntx.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions